Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma
Despite the availability of novel treatments for multiple myeloma, resistance to chemotherapy inevitably develops. We retrospectively reviewed the outcomes of patients with relapsed and/or refractory disease treated with modified hyperCVAD (n = 15) or bortezomib-hyperCAD (n = 18). Effectiveness and safety outcomes were similar in each group, with the entire cohort of patients demonstrating an overall response rate of 42%.
Publication date: Available online 13 November 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Yutong Wang, Li Bao, Bin Chu, Shan Gao, Minqiu Lu, Lei Shi, Lina Fu, Lijuan Fang, Qiuqing Xiang
In conclusion, while ATC was superior to CVP, clinical outcomes (TTP/PFS/OS) were similar in comparison to BD chemotherapy for patients with Grade 3A FL.
ConclusionRapid peripheral blast clearance after 7+3 induction demonstrated a significant improvement in specificity compared to D14BM, while maintaining similar sensitivity. Neither of these methods were reliably specific tools for the decision of early re-induction, despite their prognostic value. Our findings indicate that morphological cellularity in D14BM is an independent prognostic factor for OS and RFS, regardless of blast percentage, and that ≤10% cellularity defines D14BM hypoplasia.
ConclusionsOutcomes of RD-RCHOP chemotherapy were comparable to those of standard dose R-CHOP or previous dose-adjusted R-CHOP chemotherapy. In the future, strategies such as tailored therapy based on the geriatric assessment are needed to determine the chemotherapeutic dosage.
ConclusionResults of real-life studies differ from those found by prospective trials. Accordingly, early actions and supportive care are still needed, aiming to decrease toxicity, especially in developing countries.
Follicular Lymphoma (FL) is a common form of non-Hodgkin lymphoma with a wide spectrum of presentation. While Grade 1-2 FL is considered low-grade and Grade 3B FL is approached as an aggressive lymphoma, the management of Grade 3A FL remains a controversy. We performed a retrospective, multicenter analysis of patients aged ≥ 18 years with advanced stage 3-4 Grade 3A FL diagnosed between January 2006-July 2016. Patients were stratified by frontline chemotherapy regimen: anthracycline based (ATC), bendamustine (BD), and cyclophosphamide-vincristine-prednisone (CVP).
To evaluate the efficacy and toxicity of reduced-dose (RD) rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone (RCHOP) chemotherapy for elderly patients with diffuse large B-cell lymphoma (DLBCL), 53 patients aged ≥ 65 years in South Korea, were enrolled in this study. RD-RCHOP chemotherapy showed comparable survival benefits, compared to those of the previous reduced dose of CHOP-like chemotherapy plus rituximab.
Multiple myeloma (MM) is a malignant monoclonal plasma cell disorder that accounts for 10% of all hematological malignancies.1, 2 The survival of patients with MM has improved significantly in the last decade due to a combination of immunomodulatory agents, corticosteroids, and proteasome inhibitors.3, 4 Meanwhile, multidrug therapy and long-term treatment have raised the incidence of treatment-related cardiovascular events (CVEs). CVEs are increasingly relevant to prognosis and even contribute to early mortality in patients with MM.
The presence of recurrent genetic mutations in the myeloblasts of patients with acute myeloid leukemia (AML) are prognostic and incorporated into risk stratification systems of both the National Comprehensive Cancer Network and European Leukemia Network.1 In patients with FLT3-internal tandem duplications (FLT3-ITD) or tyrosine kinase domain mutations (TKD) small molecule inhibitors of the resultant mutant proteins in combination with cytotoxic chemotherapy can improve overall survival in newly diagnosed AML patients with a FLT3 mutation.
Conclusionsand Relevance: The combination of rituximab and bendamustine warrants further investigation in the treatment of HS, especially those originating from prior follicular lymphoma. Modern immunohistochemical and molecular profiling techniques are beginning to reveal heterogeneity amongst HS tumors and potentially therapeutic targets.